Fueling AI Drug Development with Patient Biology

While AI has been seductive in its promise for revolutionizing drug development, one of the constraints remains the quality of the data that is used by any given platform. BPG Bio, an early innovator in the application of AI to drug development as Berg, is taking what it calls a “biology-first” approach. It capitalizes on its proprietary biobank to conduct multi-omics analysis to understand the biological mechanisms of diseases. We spoke to Niven Narain, CEO of BPGbio, about how the company’s platform technology uncovers novel targets, its evolution from its start as Berg, and how the platform continues to provide insight into experimental therapies after they advance to the clinic.